ArticleTranslational psychiatry2025
Attention and inhibition deficits in narcolepsy type 1: behavioral and electrophysiological markers.
Article in Translational psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Narcolepsy: immunity, neural circuitry, and brain network reconfiguration.Frontiers in immunology · 2026Review
- Medication Treatment Modulates Sleep Architecture and Cognitive-Related Cortical Hemodynamics in Narcolepsy Type 1.Nature and science of sleep · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Cognitive impairments in narcolepsy type 1 (NT1) significantly compromise daily functioning, but their neural mechanisms remain unclear. This study employed multimodal electroencephalography (EEG) analyses to investigate electrophysiological substrates of attention and inhibition deficits in NT1 and their association with clinical characteristics, particularly orexin deficiency. High-density EEG recordings were acquired during a Go/NoGo task from 39 NT1 patients and 41 age-/sex-matched healthy controls. Behavioral analyses revealed that compared to controls, NT1 patients exhibited significantly prolonged reaction times and increased errors across both Go and NoGo conditions. Electrophysiological analyses demonstrated that NT1 patients showed: (1) delayed Go-P3 latencies, meaning impaired response preparation; (2) reduced NoGo-P3 amplitudes, reflecting deficient inhibitory control; and (3) attenuated theta-band power and inter-trial phase consistency across conditions. Notably, decreased theta-band power correlated with both lower orexin levels and slower reaction times. This suggests that altered theta-band activity may represent a core neural substrate linking the underlying pathophysiology (i.e., orexin deficiency) to its clinical cognitive manifestations. Thus, we propose theta-band oscillations as a potential clinically translatable biomarker for NT1-related cognitive deficits, with promising implications for objective monitoring of disease progression and developing EEG-targeted neuromodulation therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.